
AstraZeneca fell 0.9% from $188.41 to $186.76, behind the S&P 500's +7.8%. Its worst day was Aug 3 (−6.9%), and its low came Aug 4 at $155.62.
Feb 2, 2026 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $2.12 missed the $2.18 estimate on $15.5B revenue (est. $15.6B).
+2.9% · S&P 500 −0.3%
EPS of $2.58 beat the $1.53 estimate on $15.3B revenue (est. $14.9B).
Story events cover the past 12 months · Times ET
−0.8% · S&P 500 0.0%
AstraZeneca shares rose 6.1%, while the S&P 500 fell 0.1%.
+6.1% · S&P 500 −0.1%
EPS of $2.63 beat the $1.52 estimate on $15.4B revenue (est. $15.4B).
+0.2% · S&P 500 0.0%
AstraZeneca closed at its lowest level of the year, 17.4% below where the year started.
−1.5% · S&P 500 +1.8%
EPS of $2.79 beat the $1.44 estimate on $16.2B revenue (est. $16.0B).
+7.0%, the year's best day · S&P 500 −1.8%
Where it ended: a close of $186.76 on Nov 10, 2026.
Replay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AZN and SPY from Benzinga historical bars. Not investment advice.